Seqens Seqens

X
[{"orgOrder":0,"company":"OncoBeta","sponsor":"NanoMab Technology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NanoMab and OncoBeta Outline the Pathway to a Strategic Alliance and Supply Agreement Focused on the Secure Supply of Rhenium-188","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"},{"orgOrder":0,"company":"OncoBeta","sponsor":"Avion Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avion Medical Skin Centres to Offer Innovative Treatment for Non-Melanoma Skin Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by OncoBeta

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Traditional treatment methods typically involve surgery, which may have a risk of scarring or loss of function, treatment with Rhenium-SCT (Rhenium-188) employs a non-invasive superficial application of a paste containing ß-emitting particles directly to the lesion.

            Lead Product(s): Rhenium-188

            Therapeutic Area: Oncology Product Name: Rhenium-SCT

            Highest Development Status: Approved Product Type: Small molecule

            Recipient: Avion Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement June 23, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The Heads of Terms will initiate a Strategic Partnership and Supply Agreement for the development of Rhenium-188 API solutions that are appropriate for labelling the NanoMab range of nanobodies for the production of therapeutic radiopharmaceuticals.

            Lead Product(s): Rhenium-188

            Therapeutic Area: Oncology Product Name: Rhenium-188

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: NanoMab Technology

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement October 27, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY